{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:03:12Z","timestamp":1791342192133,"version":"4.3.1"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,26]],"date-time":"2016-12-26T00:00:00Z","timestamp":1482710400000},"content-version":"vor","delay-in-days":360,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mtm.2016.34","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T10:49:32Z","timestamp":1464173372000},"page":"16034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":217,"special_numbering":"C","title":["Clinical development of gene therapy: results and lessons from recent successes"],"prefix":"10.1016","volume":"3","author":[{"given":"Sandeep RP","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Markusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moanaro","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"High","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mtm.2016.34_bib1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1181937","article-title":"Medicine. A comeback for gene therapy","volume":"326","author":"Naldini","year":"2009","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib2","first-page":"105","article-title":"Two decades of clinical gene therapy\u2013success is finally mounting","volume":"9","author":"Herzog","year":"2010","journal-title":"Discov Med"},{"key":"10.1038\/mtm.2016.34_bib3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/mt.2015.20","article-title":"Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/mt.2015.38","article-title":"A shot in the bone corrects a genetic disease","volume":"23","author":"Brown","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/mtm.2016.34_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2013.07.052","article-title":"Primary Immune Deficiency Treatment Consortium (PIDTC) report","volume":"133","author":"Griffith","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/mtm.2016.34_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1038\/mtm.2016.34_bib10","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib12","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib13","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib14","doi-asserted-by":"crossref","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib15","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1038\/mtm.2016.34_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib18","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1038\/mtm.2016.34_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtm.2016.34_bib20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2009.179","article-title":"Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors","volume":"17","author":"Modlich","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/mt.2011.204","article-title":"Evaluation of residual promoter activity in \u03b3-retroviral self-inactivating (SIN) vectors","volume":"20","author":"Xu","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib23","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2014-12-616003","article-title":"Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1","volume":"125","author":"Touzot","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib24","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib25","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nm0798-775","article-title":"T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates","volume":"4","author":"Kohn","year":"1998","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.34_bib26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nm1095-1017","article-title":"Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency","volume":"1","author":"Kohn","year":"1995","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.34_bib27","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1172\/JCI31666","article-title":"Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy","volume":"117","author":"Aiuti","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/mtm.2016.34_bib28","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2012-08-446559","article-title":"Gene therapy for ADA-SCID: defining the factors for successful outcome","volume":"120","author":"Gaspar","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s10875-015-0157-1","article-title":"Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning","volume":"35","author":"Otsu","year":"2015","journal-title":"J Clin Immunol"},{"issue":"Suppl 2","key":"10.1038\/mtm.2016.34_bib30","first-page":"S167","article-title":"Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency","volume":"34","author":"Gaspar","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1038\/mtm.2016.34_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/hum.2015.047","article-title":"Clinical applications of gene therapy for primary immunodeficiencies","volume":"26","author":"Cicalese","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib32","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib33","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2013long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40265-014-0223-7","article-title":"Gene therapy for primary immunodeficiencies: current status and future prospects","volume":"74","author":"Qasim","year":"2014","journal-title":"Drugs"},{"key":"10.1038\/mtm.2016.34_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood.V126.23.259.259","article-title":"Safety and clinical benefit of lentiviral hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome","volume":"126","author":"Ferrua","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood.V126.23.260.260","article-title":"Gene therapy using a self-inactivating lentiviral vector improves clinical and laboratory manifestations of Wiskott-Aldrich syndrome","volume":"126","author":"Chu","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2010.232","article-title":"Gene therapy of chronic granulomatous disease: the engraftment dilemma","volume":"19","author":"Grez","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.34_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.V126.23.201.201","volume":"126","author":"Walters","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.V126.23.202.202","article-title":"Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector","volume":"126","author":"Cavazzana","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2016.57","article-title":"Gene therapy for hemoglobinopathies: tremendous successes and remaining caveats","volume":"24","author":"Malik","year":"2016","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat Genet"},{"key":"10.1038\/mtm.2016.34_bib43","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.34_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.34_bib46","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1038\/mtm.2015.29","article-title":"AAV capsid CD8+ T cell epitopes are highly conserved across AAV serotypes","volume":"2","author":"Hui","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1038\/mtm.2016.34_bib47","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood-2006-03-010181","article-title":"Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates","volume":"109","author":"Nathwani","year":"2007","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib48","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib49","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib50","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib51","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2741\/4324","article-title":"Gene therapy for hemophilia","volume":"20","author":"Rogers","year":"2015","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1038\/mtm.2016.34_bib52","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/mt.2015.56","article-title":"Moving forward toward a cure for hemophilia B","volume":"23","author":"VandenDriessche","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib54","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/hum.2008.084","article-title":"Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B","volume":"20","author":"Brunetti-Pierri","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib55","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","article-title":"Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice","volume":"120","author":"Cantore","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib56","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib57","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2004-08-2990","article-title":"Factor IX variants improve gene therapy efficacy for hemophilia B","volume":"105","author":"Schuettrumpf","year":"2005","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/mt.2013.188","article-title":"Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice","volume":"22","author":"Suwanmanee","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib60","first-page":"87, 13 87","article-title":"Update on a phase 1\/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B","volume":"13","author":"Monahan","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1038\/mtm.2016.34_bib61","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/mt.2015.135","article-title":"Hemophilia gene therapy: caught between a cure and an immune response","volume":"23","author":"Herzog","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib62","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/mt.2014.139","article-title":"Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants","volume":"22","author":"Marsic","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib63","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1038\/ncomms8339","article-title":"Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model","volume":"6","author":"Bissig-Choisat","year":"2015","journal-title":"Nat Commun"},{"key":"10.1038\/mtm.2016.34_bib64","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"Lisowski","year":"2014","journal-title":"Nature"},{"key":"10.1038\/mtm.2016.34_bib65","doi-asserted-by":"crossref","first-page":"14006","DOI":"10.1038\/mtm.2014.6","article-title":"AAV shuffles to the liver: commentary on Lisowski","volume":"1","author":"Schaffer","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1038\/mtm.2016.34_bib66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat Rev Genet"},{"key":"10.1038\/mtm.2016.34_bib67","doi-asserted-by":"crossref","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib68","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/mt.2013.176","article-title":"Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors","volume":"21","author":"Hoffman","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib69","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib70","doi-asserted-by":"crossref","first-page":"14033","DOI":"10.1038\/mtm.2014.33","article-title":"B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1038\/mtm.2016.34_bib71","doi-asserted-by":"crossref","first-page":"14030","DOI":"10.1038\/mtm.2014.30","article-title":"Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia","volume":"1","author":"Sarkar","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1038\/mtm.2016.34_bib72","doi-asserted-by":"crossref","first-page":"14013","DOI":"10.1038\/mtm.2014.13","article-title":"Development of gene transfer for induction of antigen-specific tolerance","volume":"1","author":"Sack","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1038\/mtm.2016.34_bib73","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1038\/mtm.2016.34_bib74","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib75","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib76","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib77","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-386509-0.00010-7","article-title":"Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy","volume":"507","author":"Cartier","year":"2012","journal-title":"Methods Enzymol"},{"key":"10.1038\/mtm.2016.34_bib78","doi-asserted-by":"crossref","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib79","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/mt.2015.122","article-title":"Benefits of neuronal preferential systemic gene therapy for neurotransmitter deficiency","volume":"23","author":"Lee","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib80","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib81","doi-asserted-by":"crossref","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib82","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1089\/hum.2013.005","article-title":"Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates","volume":"24","author":"Samaranch","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib83","article-title":"Viral vectors for therapy of neurologic diseases","author":"Choudhury","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1038\/mtm.2016.34_bib84","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib85","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1089\/hum.2009.086","article-title":"Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year","volume":"20","author":"Cideciyan","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib86","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/mt.2012.280","article-title":"A comprehensive review of retinal gene therapy","volume":"21","author":"Boye","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib88","doi-asserted-by":"crossref","first-page":"15112","DOI":"10.1073\/pnas.0807027105","article-title":"Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics","volume":"105","author":"Cideciyan","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2016.34_bib89","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1038\/mtm.2016.34_bib91","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib92","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2","volume":"120","author":"Testa","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1038\/mtm.2016.34_bib93","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"key":"10.1038\/mtm.2016.34_bib94","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2015.29004.sch","article-title":"Investor Outlook: Significance of the Positive LCA2 Gene Therapy Phase III Results","volume":"26","author":"Schimmer","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1038\/mtm.2016.34_bib95","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","article-title":"Improvement and decline in vision with gene therapy in childhood blindness","volume":"372","author":"Jacobson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib96","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib97","doi-asserted-by":"crossref","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","article-title":"AAV2 gene therapy readministration in three adults with congenital blindness","volume":"4","author":"Bennett","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib98","doi-asserted-by":"crossref","first-page":"e16588","DOI":"10.1371\/journal.pone.0016588","article-title":"Gene therapy regenerates protein expression in cone photoreceptors in Rpe65(R91W\/R91W) mice","volume":"6","author":"Kostic","year":"2011","journal-title":"PLoS One"},{"key":"10.1038\/mtm.2016.34_bib99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.10-6138","article-title":"Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis","volume":"52","author":"Li","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mtm.2016.34_bib100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/gt.2012.63","article-title":"RPE65 gene therapy slows cone loss in Rpe65-deficient dogs","volume":"20","author":"Mowat","year":"2013","journal-title":"Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib101","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2016.34_bib102","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/mtm.2015.13","article-title":"Silencing p75(NTR) prevents proNGF-induced endothelial cell death and development of acellular capillaries in rat retina","volume":"2","author":"Shanab","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1038\/mtm.2016.34_bib103","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase \u00bd clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1038\/mtm.2016.34_bib104","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamaophthalmol.2013.7630","article-title":"Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial","volume":"132","author":"Koilkonda","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1038\/mtm.2016.34_bib105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cgt.2014.71","article-title":"Manufacturing genetically modified T cells for clinical trials","volume":"22","author":"Gee","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mtm.2016.34_bib106","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2016.34_bib107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jocn.2013.03.012","article-title":"Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma","volume":"21","author":"Choi","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1038\/mtm.2016.34_bib108","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib109","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib110","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib111","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib112","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib113","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1038\/mtm.2016.34_bib114","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib115","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.34_bib116","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib117","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib118","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib119","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1038\/mtm.2016.34_bib120","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1038\/mtm.2016.34_bib121","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib122","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/mt.2014.43","article-title":"Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells","volume":"22","author":"Wang","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib123","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mt.2015.102","article-title":"HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells","volume":"23","author":"Zhen","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib124","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-05-1485","article-title":"Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma","volume":"12","author":"Duval","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mtm.2016.34_bib125","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib126","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1038\/mtm.2016.34_bib127","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib128","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.34_bib129","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/mtm.2016.34_bib130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib131","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.34_bib132","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"10.1038\/mtm.2016.34_bib133","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.34_bib134","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mtm.2016.34_bib135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mtm.2016.34_bib136","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nbt.3055","article-title":"In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9","volume":"33","author":"Swiech","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtm.2016.34_bib137","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtm.2016.34_bib138","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature13864","article-title":"Promoterless gene targeting without nucleases ameliorates haemophilia B in mice","volume":"517","author":"Barzel","year":"2015","journal-title":"Nature"},{"key":"10.1038\/mtm.2016.34_bib139","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In vivo genome editing restores haemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"key":"10.1038\/mtm.2016.34_bib140","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/mt.2015.80","article-title":"Molecular therapy special issue on gene editing technologies and applications","volume":"23","author":"Frederickson","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.34_bib141","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt.3408","article-title":"Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors","volume":"33","author":"Wang","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtm.2016.34_bib142","doi-asserted-by":"crossref","first-page":"307ra156","DOI":"10.1126\/scitranslmed.aac5530","article-title":"Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template","volume":"7","author":"Sather","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116301772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116301772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:20:56Z","timestamp":1762420856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050116301772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":142,"alternative-id":["S2329050116301772"],"URL":"https:\/\/doi.org\/10.1038\/mtm.2016.34","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical development of gene therapy: results and lessons from recent successes","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mtm.2016.34","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Official journal of the American Society of Gene & Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"16034"}}